Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y12 Receptor Antagonists


. 2022 Oct;52(10):737-754.

doi: 10.4070/kcj.2022.0162.


Item in Clipboard


Leonid N Maslov et al.

Korean Circ J.

2022 Oct.


Ischemic and reperfusion injuries of the heart underlie the pathogenesis of acute myocardial infarction (AMI) and sudden cardiac death. The mortality rate is still high and is 5-7% in patients with ST-segment elevation myocardial infarction. The review is devoted to pharmacological approaches to limitation of ischemic and reperfusion injuries of the heart. The article analyzes experimental evidence and the clinical data on the effects of P2Y12 receptor antagonists on the heart’s tolerance to ischemia/reperfusion in animals with coronary artery occlusion and reperfusion and also in patients with AMI. Chronic administration of ticagrelor prevented adverse remodeling of the heart. There is evidence that sphingosine-1-phosphate is the molecule that mediates the infarct-reducing effect of P2Y12 receptor antagonists. It was discussed a role of adenosine in the cardioprotective effect of ticagrelor.


Cardiac remodeling; Heart; Ischemia; Purinergic P2Y12 receptor antagonists; Reperfusion.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Similar articles

Source link

Back to top button